Drug interactions between hormonal contraceptives and antiretrovirals

K. Nanda, G. Stuart, J. Robinson, Andrew L Gray, N. Tepper, M. E. Gaffield
{"title":"Drug interactions between hormonal contraceptives and antiretrovirals","authors":"K. Nanda, G. Stuart, J. Robinson, Andrew L Gray, N. Tepper, M. E. Gaffield","doi":"10.1097/QAD.0000000000001392","DOIUrl":null,"url":null,"abstract":"Objective: To summarize published evidence on drug interactions between hormonal contraceptives and antiretrovirals. Design: Systematic review of the published literature. Methods: We searched PubMed, POPLINE, and EMBASE for peer-reviewed publications of studies (in any language) from inception to 21 September 2015. We included studies of women using hormonal contraceptives and antiretrovirals concurrently. Outcomes of interest were effectiveness of either therapy, toxicity, or pharmacokinetics. We used standard abstraction forms to summarize and assess strengths and weaknesses. Results: Fifty reports from 46 studies were included. Most antiretrovirals whether used for therapy or prevention, have limited interactions with hormonal contraceptive methods, with the exception of efavirenz. Although depot medroxyprogesterone acetate is not affected, limited data on implants and combined oral contraceptive pills suggest that efavirenz-containing combination antiretroviral therapy may compromise contraceptive effectiveness of these methods. However, implants remain very effective despite such drug interactions. Antiretroviral plasma concentrations and effectiveness are generally not affected by hormonal contraceptives. Conclusion: Women taking antiretrovirals, for treatment or prevention, should not be denied access to the full range of hormonal contraceptive options, but should be counseled on the expected rates of unplanned pregnancy associated with all contraceptive methods, in order to make their own informed choices.","PeriodicalId":355297,"journal":{"name":"AIDS (London, England)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"66","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000001392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 66

Abstract

Objective: To summarize published evidence on drug interactions between hormonal contraceptives and antiretrovirals. Design: Systematic review of the published literature. Methods: We searched PubMed, POPLINE, and EMBASE for peer-reviewed publications of studies (in any language) from inception to 21 September 2015. We included studies of women using hormonal contraceptives and antiretrovirals concurrently. Outcomes of interest were effectiveness of either therapy, toxicity, or pharmacokinetics. We used standard abstraction forms to summarize and assess strengths and weaknesses. Results: Fifty reports from 46 studies were included. Most antiretrovirals whether used for therapy or prevention, have limited interactions with hormonal contraceptive methods, with the exception of efavirenz. Although depot medroxyprogesterone acetate is not affected, limited data on implants and combined oral contraceptive pills suggest that efavirenz-containing combination antiretroviral therapy may compromise contraceptive effectiveness of these methods. However, implants remain very effective despite such drug interactions. Antiretroviral plasma concentrations and effectiveness are generally not affected by hormonal contraceptives. Conclusion: Women taking antiretrovirals, for treatment or prevention, should not be denied access to the full range of hormonal contraceptive options, but should be counseled on the expected rates of unplanned pregnancy associated with all contraceptive methods, in order to make their own informed choices.
激素避孕药和抗逆转录病毒药物之间的药物相互作用
目的:总结已发表的激素避孕药与抗逆转录病毒药物相互作用的证据。设计:系统回顾已发表的文献。方法:我们检索PubMed、POPLINE和EMBASE,检索从成立到2015年9月21日的同行评议的研究出版物(任何语言)。我们纳入了同时使用激素避孕药和抗逆转录病毒药物的妇女的研究。关注的结果是治疗的有效性、毒性或药代动力学。我们使用标准的抽象形式来总结和评估优点和缺点。结果:纳入46项研究的50篇报道。大多数抗逆转录病毒药物,无论是用于治疗还是预防,与激素避孕方法的相互作用有限,但依非韦伦除外。虽然储存的醋酸甲孕酮不受影响,但关于植入物和联合口服避孕药的有限数据表明,含有依非韦伦的联合抗逆转录病毒治疗可能会损害这些方法的避孕效果。然而,尽管药物相互作用,植入物仍然非常有效。抗逆转录病毒血浆浓度和有效性一般不受激素避孕药的影响。结论:不应拒绝接受抗逆转录病毒药物治疗或预防的妇女使用各种激素避孕方法,而应告知所有避孕方法的预期意外怀孕率,以便作出自己的知情选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信